{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-000292","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.980237+00:00","generated_at":"2026-05-28T09:47:42.975289+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Gyre Therapeutics chairman Ying Luo resigns; Ping Zhang appointed as lead independent director","bullets":["Ying Luo resigned as Chairman and Board member (eff. Dec 31, 2024) to focus on other responsibilities at GNI Group Ltd.","Ping Zhang appointed Class I director, lead independent director, and Nominating Committee member (eff. Jan 5, 2025).","Songjiang Ma appointed Chairman of Gyre Pharmaceuticals Board (eff. Jan 6, 2025).","Zhang is Managing Partner of String Capital and serves on the boards of GNI and Asian Star Co."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-000292","json":"https://secwatch.observer/filing/0001140361-25-000292.json","markdown":"https://secwatch.observer/filing/0001140361-25-000292.md","text":"https://secwatch.observer/filing/0001140361-25-000292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000292/0001140361-25-000292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000292/ef20041130_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T09:47:42.975289+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da8f4d6f16","claim":"Ping Zhang was appointed as Class I director and lead independent director at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On January 5, 2025, the Board appointed Ping Zhang as a Class I director of the Company. Mr. Zhang was also appointed as the lead independent director of the Board and a member of the Nominating Committee.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000292/0001140361-25-000292-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director and lead independent director"}],"fact_type":"executive_change"},{"claim_id":"e0d6c3e4ec","claim":"Ying Luo resigned as Chairman at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On December 31, 2024, Ying Luo, Ph. D. resigned as Chairman and a member of the board of directors (the “Board”) of Gyre Therapeutics, Inc. (the “Company”), as chair and a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”) and as Chairman and a member of the board of directors of Gyre Pharmaceuticals Co., Ltd. (the “Gyre Pharmaceuticals Board”), the Company’s majority indirectly owned subsidiary (“Gyre Pharmaceuticals”), effective immediately, due to his need to focus on other responsibilities at GNI Group Ltd.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125000292/0001140361-25-000292-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}